Abstract
Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children’s Hospital (ACH), a clinical PGx laboratory-based test was developed and implemented to provide guidance on 66 pediatric medications for genotype-guided dosing. This PGx test consists of 174 single nucleotide polymorphisms (SNPs) targeting 23 clinically actionable PGx genes or gene variants. Individual genotypes are processed to provide per-gene discrete results in star-allele and phenotype format. These results are then integrated into EPIC- EHR. Genomic indicators built into EPIC-EHR provide the source for clinical decision support (CDS) for clinicians, providing genotype-guided dosing.
Highlights
Introduction distributed under the terms andAdverse drug reactions (ADRs) are the fourth leading cause of death in the USA [1]and account for 135K deaths per year with an economic burden of over USD 136 billion [2,3].A systematic review of prospective studies showed that 5.3% of hospital admissions were associated with ADRs [4]
The following project details were reviewed by the Institutional Review Board (IRB) at the University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, which considered the project to be a development and implementation of an internal genetics panel at Arkansas Children’s Hospital (ACH) for the purpose of improving local patient care that, as such, did not meet the regulatory definition of research or require IRB oversight (PI: Schaefer; IRB #-262792)
It was determined that there was a clear interest by the stakeholders and the Precision Medicine (PM) Group in the development and implementation of a PGx program at ACH that would be of high priority and allow us to provide personalized drug therapy to our patients at ACH
Summary
Introduction distributed under the terms andAdverse drug reactions (ADRs) are the fourth leading cause of death in the USA [1]and account for 135K deaths per year with an economic burden of over USD 136 billion [2,3].A systematic review of prospective studies showed that 5.3% of hospital admissions were associated with ADRs [4]. Adverse drug reactions (ADRs) are the fourth leading cause of death in the USA [1]. Account for 135K deaths per year with an economic burden of over USD 136 billion [2,3]. A systematic review of prospective studies showed that 5.3% of hospital admissions were associated with ADRs [4]. These are alarming statistics that illustrate the potential of conditions of the Creative Commons.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
